LABHIGH SIGNALOPERATIONAL10-K

LAB divested SomaLogic to Illumina in June 2025, generating significant proceeds while dramatically reducing debt by 99.5% and cutting R&D expenses by 58.4%.

This represents a major strategic pivot where LAB sold a key business unit it had just acquired in 2024, suggesting either financial necessity or strategic refocusing. The divestiture appears to have been executed at favorable terms given the massive debt reduction, but investors should monitor whether LAB can sustain operations with significantly reduced scale and capabilities.

Comparing 2026-03-16 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

LAB's financials reflect the dramatic impact of divesting SomaLogic, with revenue surging 311.9% (likely including divestiture proceeds or full-year SomaLogic contribution before sale) while operating assets like inventory and receivables declined 50-60%. The company eliminated nearly all debt ($63.5M to $299K) and cut R&D spending by 58.4%, but current liabilities increased 64.4%, suggesting potential working capital pressures. Despite the strategic restructuring, LAB still posted significant losses, though operating cash flow and net losses both improved by approximately 46-48%.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+311.9%
$24.7M→$101.9M

Strong top-line growth of 311.9% — accelerating demand or successful expansion into new markets.

Total Debt
Balance Sheet
-99.5%
$63.5M→$299K

Debt reduced 99.5% — deleveraging strengthens balance sheet and reduces financial risk.

Current Liabilities
Balance Sheet
+64.4%
$65.9M→$108.3M

Current liabilities surged 64.4% — significant near-term obligations; verify ability to meet short-term debt.

Accounts Receivable
Balance Sheet
-60%
$33.6M→$13.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

R&D Expense
P&L
-58.4%
$62.4M→$26.0M

R&D spending cut 58.4% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
-51%
$40.7M→$20.0M

Inventory drawn down 51% — strong sell-through or deliberate destocking; watch for supply constraints.

Gross Profit
P&L
-49.5%
$84.3M→$42.5M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Cash Flow
Cash Flow
+48.2%
-$143.5M→-$74.3M

Operating cash flow surged 48.2% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+46.1%
-$138.9M→-$74.9M

Net income grew 46.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+37.1%
-$175.2M→-$110.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-11
ADDED
As of March 12, 2026, there were 390,071,506 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 42 ITEM 7A.
export controls and tariffs, potential growth opportunities, market growth expectations, the effects of competition, cost structure optimization, acceleration of growth, potential merger and acquisition activity and restructuring plans (including expense reduction activities, modifications to the scope of our proteomic and genomics businesses and discontinuing of certain product lines), our expectations regarding the benefits and integration of acquired businesses and/or products and the transaction with Illumina, Inc.
( Illumina ), including the financial impact of the transaction, potential earnout payments and royalty streams, potential integration, restructuring and transition-related disruption from the transaction, and potential stockholder litigation from the transaction.
On June 22, 2025, we entered into a Stock Purchase Agreement (the Purchase Agreement ) with Illumina.
+7 more — sign up free →
REMOVED
As of March 2, 2025, there were 378,986,362 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 57 ITEM 7A.
Forward-looking statements include information concerning our possible or assumed future cash flow, revenue, sources of revenue and results of operations, cost of product revenue and product margin, operating and other expenses, unit sales and the selling prices of our products, business strategies, financing plans, expansion of our business, investments to expand our customer base, plans for our products, competitive position, industry environment, anticipated National Institutes of Health funding pressures, the expected effect from U.S.
export controls and tariffs, potential growth opportunities, market growth expectations, the effects of competition, cost structure optimization, acceleration of growth, potential merger and acquisition (M A) activity and restructuring plans (including expense reduction activities, modifications to the scope of our proteomic and genomics businesses and discontinuing of certain product lines) and our expectations regarding the benefits and integration of acquired businesses and/or products.
On January 5, 2024, we completed our merger with SomaLogic, Inc.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →